Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
The ANCHOR-1 and ANCHOR-2 trials of the long-acting anti-interleukin (IL)-5 monoclonal antibody depemokibab in chronic rhinosinusitis with nasal polyposis demonstrated the safety and statistical efficacy of the drug compared to placebo. However, its clinical benefits appear limited compared to other biologic therapies. The reduced dosing interval may improve adherence, but further research is needed to identify the most responsive patients.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.medj.2025.100674 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Effects of fibroblasts-derived exosomal FAP in regulating EMT in epithelial cells from chronic rhinosinusitis.
Braz J Otorhinolaryngol
September 2025
Zhejiang University, College of Medicine, Department of Otolaryngology, Hangzhou City, Zhejiang Province, China.
Objectives: Exosomes play a crucial role in intercellular communication and may contribute to the development of various diseases. Nevertheless, their role in Nasal Polyps (NPs) remains poorly understood. Herein, Nasal Polyp Fibroblasts (NPF) were used to release exosomes, and epithelial cells were cocultured with NPF-derived exosomes to analyze Epithelial-Mesenchymal Transition (EMT) in Chronic Rhinosinusitis (CRS).
View Article and Find Full Text PDFOne-year efficacy of Dupilumab in sense of smell, nasal polyp score and quality of life in CRSwNP patients: A real-world multicenter study in Brazil.
Braz J Otorhinolaryngol
September 2025
Faculdade de Medicina de Ribeirão Preto - Universidade de São Paulo, São Paulo, SP, Brazil.
Introduction: Chronic rhinosinusitis with nasal polyp (CRSwNP) is a predominant type 2 inflammatory disease, affecting the sense of smell and quality of life. Loss of smell compromises physical and emotional health, creating negative impacts and its treatment in CRSwNP is challenging.
Aim: To present the outcomes of dupilumab in olfactory function, Nasal Polyp Score (NPS) and quality of life in Brazilian patients with severe CRSwNP.
Chronic rhinosinusitis in 292 adults with primary antibody deficiencies.
J Allergy Clin Immunol Pract
September 2025
Department of Medicine, University of California, Irvine, USA. Electronic address:
Efficacy and safety of intranasal corticosteroids combined with mucoactive drugs for chronic rhinosinusitis.
Int Immunopharmacol
September 2025
ENT Institute and Department of Otorhinolaryngology, Affiliated Eye and ENT Hospital of Fudan University, Shanghai, China. Electronic address:
Background: Chronic rhinosinusitis (CRS) leads to a burden in life and economy. Better therapies need to be explored.
Objective: This stage I study aims to explore the efficacy and safety of intranasal corticosteroids combined with mucoactive drugs for CRS.
The Risk of Rheumatic Disorders Among Patients With Rhinosinusitis: A Systematic Review and Meta-Analysis.
Int Forum Allergy Rhinol
September 2025
Division of Otolaryngology Head & Neck Surgery, University of British Columbia, Vancouver, British Columbia, Canada.
Background: Emerging evidence suggests a possible link between rhinosinusitis and systemic rheumatic diseases; however, no meta-analysis has comprehensively examined this association to date. We aimed to investigate if patients with rhinosinusitis have a predisposition to unmasking rheumatic diseases compared to individuals without rhinosinusitis.
Methods: A comprehensive search in MEDLINE, Embase, Cochrane Library, and Web of Science was conducted until February 2025 for studies characterizing rheumatic disease incidence, prevalence, and risk in cohorts of rhinosinusitis patients.